President Donald Trump wants to stop directing federal funds to the nation's university centers on developmental disabilities, multiple Individuals with Disabilities Education Act programs and much ...
In a recent study published in Neurology - Neuroimmunology Neuroinflammation, researchers investigated the impact of coronavirus disease 2019 (COVID-19) on the progression of clinical disability in ...
An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...
Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving smoldering inflammation and neurodegeneration that drives disability in ...
How do we assess the needs of people with severe multiple disabilities? Unable to communicate verbally and physically, this population has nearly no possibility of expressing itself. Thanks to ...
Share on Pinterest Scientists are trying to find blood biomarkers that may help predict the course of disease in MS. Betsie Van der Meer/Getty Images As of 2020, about 2.8 million people globally have ...
Share on Pinterest A recent study reports that starting treatment at the first signs of MS symptoms could help slow disease progression. Jennifer Blount/Getty Images A recent study finds getting ...
A phase 3 study has shown that tolebrutinib, a drug being tested in treating non-relapsing secondary progressive multiple sclerosis, slowed the progression of disability in patients. The trial ...
To qualify for the DTC, you must complete the Canada Revenue Agency ’s Form T2201, Disability Tax Credit Certificate, upon ...
Please provide your email address to receive an email when new articles are posted on . Medical student burnout is an important quality assessment metric in medicine. Students with multiple ...
Please provide your email address to receive an email when new articles are posted on . Tolebrutinib was associated with a 31% reduced risk for 6-month confirmed disability progression vs. placebo.